Pediatric clinical trials offer unique challenges. They are often associated with the highest placebo response rates.
Different age-appropriate versions and observer versions complicate clinical outcome assessments. And obtaining consent and assent is a more complex process.
In episode one of our "Clinical Viewpoints" video series, Dr. Joan Busner, chair of ISCTM Orphan Diseases Working Group, provides insights from her considerable experience in designing and supporting pediatric and rare disease clinical trials.
